drugset / Trial / NCT06662383

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

NCT06662383

Phase 3 Active not recruiting 800 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.

Timeline

Start
2024-11-01
Primary completion
2026-11
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Retatrutide Protein / enzyme biologic Subcutaneous
Comparator Tirzepatide Peptide Subcutaneous

Indications